生长抑素与乌司他丁治疗急性胰腺炎患者的临床疗效及对胃肠功能的影响

Clinical Efficacy of Somatostatin and Ulinastatin in the Treatment of Patients with Acute Pancreatitis and its Effect on Gastrointestinal Function

目的研究生长抑素与乌司他丁治疗急性胰腺炎(AP)的临床疗效及对患者胃肠功能的影响。方法选取2021年10月-2022年10月南昌市第三医院急重症医学科收治的72例AP患者,按照随机数字表法分为对照组(36例)和观察组(36例)。对照组给予乌司他丁治疗,观察组给予生长抑素与乌司他丁治疗,比较两组临床疗效、生化指标[血淀粉酶(AMS)、白细胞(WBC)、C-反应蛋白(CRP)]、急性胰腺炎严重程度床边指数(BISAP)、胃肠功能评分、恢复时间(腹痛消失时间、通便时间、AMS恢复正常时间、住院时间)。结果观察组治疗总有效率为94.44%,高于对照组的77.78%(P<0.05);两组治疗后AMS、WBC、CRP水平均低于治疗前,且观察组AMS、WBC、CRP水平低于对照组(P<0.05);两组治疗后BISAP、胃肠功能评分均低于治疗前,且观察组BISAP、胃肠功能评分低于对照组(P<0.05);观察组腹痛消失时间、通便时间、AMS恢复正常时间及住院时间均短于对照组(P<0.05)。结论生长抑素联合乌司他丁治疗AP的疗效良好,可有效改善患者病情及胃肠功能,下调体内炎性损伤标志物水平,加快其临床恢复。

Objective To study the clinical efficacy of somatostatin and ulinastatin in the treatment of acute pancreatitis(AP)and its effect on gastrointestinal function.Methods A total of 72 patients with AP admitted to the Department of Emergency and Critical Care Medicine of Nanchang Third Hospital from October 2021 to October 2022 were selected and divided into control group(36 patients)and observation group(36 patients)according to the random number table method.The control group was treated with ulinastatin,and the observation group was treated with somatostatin and ulinastatin.The clinical efficacy,biochemical indexes[blood amylase(AMS),white blood cell(WBC),C-reactive protein(CRP)],bedside index of severity in acute pancreatitis(BISAP),gastrointestinal function score,recovery time(abdominal pain disappearance time,defecation time,AMS recovery time,hospitalization time)were compared between the two groups.Results The total effective rate of treatment in the observation group was 94.44%,which was higher than 77.78%in the control group(P<0.05).After treatment,the levels of AMS,WBC and CRP in the two groups were lower than those before treatment,and the levels of AMS,WBC and CRP in the observation group were lower than those in the control group(P<0.05).After treatment,the BISAP and gastrointestinal function scores of the two groups were lower than those before treatment,and the BISAP and gastrointestinal function scores of the observation group were lower than those of the control group(P<0.05).The disappearance time of abdominal pain,defecation time,AMS recovery time and hospitalization time in the observation group were shorter than those in the control group(P<0.05).Conclusion Somatostatin combined with ulinastatin is effective in the treatment of AP,which can effectively improve the patient's condition and gastrointestinal function,down-regulate the level of inflammatory injury markers in vivo,and accelerate its clinical recovery.